ALISO VIEJO, CA, UNITED STATES, August 29, 2025 / EINPresswire.com / -- GenBio Announces Filing of Trademark Application for Imflamoxil – GenBio, a biotechnology company dedicated to developing innovative therapies for immune and inflammatory conditions, today announced that it has filed a trademark application with the United States Patent and Trademark Office ( USPTO ) for the brand name Imflamoxil. Imflamoxil represents an important step in GenBio’s mission to advance next-generation treatmen

More than 66.7 million Americans now covered for safe, effective at-home treatment for psoriasis, eczema, and vitiligo BRYAN, Ohio, Aug. 29, 2025 /PRNewswire/ -- Phothera announced today that Cigna has updated its coverage policy to remove prior restrictions on home phototherapy, effective 7/15/2025. This change opens access for Cigna's 19.2 million covered lives nationwide, allowing eligible members with conditions such as psoriasis, eczema, and vitiligo to receive convenient, clinically proven

DUBLIN, Aug. 29, 2025 /PRNewswire/ -- A new study in Clinical and Translational Gastroenterology has demonstrated that a first-of-its-kind breath test device from FoodMarble, used as part of an app-guided program, enables clinically meaningful reductions in common digestive symptoms after only a single-week of dietary change. Continue Reading FoodMarble device and packaging FoodMarble device and app in use The study, led by researchers from Massachusetts General Hospital and Harvard Medical Sc

PENNINGTON, N.J. and AHMEDABAD, India, Aug. 29, 2025 /PRNewswire/ -- Zydus Therapeutics, a wholly owned subsidiary of Zydus Lifesciences Ltd., a global innovation led healthcare company, today announced positive topline results from the pivotal EPICS-III Phase 2(b)/3 clinical trial. In this trial, the safety and efficacy of Saroglitazar, an investigational alpha/gamma Peroxisome Proliferator-Activated Receptor (PPAR) agonist, was evaluated for the treatment of adult patients with Primary Biliary

Announcement no. 39/2025 29 August 2025 Reference is made to announcement no. 31/2025 published on 17 July 2025 (Embla Medical signs agreement to invest in a majority share in Streifeneder ortho.production GmbH). REYKJAVIK, Iceland and COPENHAGEN, Denmark, Aug. 29, 2025 /PRNewswire/ -- Embla Medical (NASDAQ Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced that the majority share investment in Streifeneder ortho.production has been completed followi

The first overall survival win for a PD-1xVEGF drug, Fosun Pharma's immune disease deal with Sitala Bio and Hutchmed's acting CEO appointment made our news this week. Akeso and Summit Therapeutics' PD-1xVEGF drug has delivered its first overall survival win in a phase 3 trial. Fosun Pharma out-licensed another immune disease candidate. Hutchmed's CEO took medical leave. And more.1. Akeso, Summit's PD-1xVEGF drug meets overall survival goal for the first time in a lung cancer trialFor th

Pro Football Hall of Famer and Ready to Rescue campaign spokesperson, Emmitt Smith, and Release Recovery Founder/CEO, Zac Clark, plan to visit several U.S. college campuses to educate on opioid emergency preparednessNew sponsorship of Mobilize Recovery's “Campus Surge” initiative brings addiction prevention and recovery support to higher education institutions GAITHERSBURG, Md., Aug. 29, 2025 (GLOBE NEWSWIRE) -- In honor of International Overdose Awareness Day (IOAD) on August 31, Emergent

Navitor is now approved as a minimally invasive alternative to surgery for patients in Europe with symptomatic, severe aortic stenosis (a common and life-threatening heart valve disease) who are at low or intermediate surgical risk CE Mark is based on safety and effectiveness data from the VANTAGE trial presented at the European Society of Cardiology (ESC) Congress 2025 and simultaneously published in JACC: Cardiovascular Interventions Updated guidelines announced for the management of valvular

- Company must regain compliance with the Nasdaq Bid Price Rule on or before the October 17, 2025 deadline - SOUTH SAN FRANCISCO, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, announced that it received a decision letter (the “Letter”) from the Nasdaq Hearings Panel (the “Panel”) on August 27, 2025, granting

HONG KONG, Aug. 29, 2025 /PRNewswire/ -- On the morning of 29 August, Guo Guangchang, Chairman of Fosun International, stated at the Company's 2025 interim results presentation that Fosun will continue to increase investment in biopharmaceuticals and focus on deepening and thoroughly developing its advantageous industries to secure a commanding global position. The interim results presentation was held in Shanghai this morning, with attendees including Chairman Guo Guangchang, Co-Chairman Wang Q